This is a routine clinical site activation with no new data, regulatory decision, or financing event. Monitor for future data readouts or regulatory milestones from the Phase 3 study for potential catalysts.
Price Chart
Executive Summary
BriaCell announced that Sunnybrook's Odette Cancer Centre has joined its pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer. This is a routine clinical site addition with no new data or regulatory milestone, providing negligible near-term stock catalyst for this micro-cap biotech.
Key Facts
- Odette Cancer Centre at Sunnybrook Health Sciences Centre joined BriaCell's Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.
- The study is described as pivotal and is listed under ClinicalTrials.gov identifier NCT06072612.
- BriaCell is a clinical-stage biotechnology company developing novel immunotherapies.
Financial Impact
No financial terms disclosed; site addition has no direct revenue or cost impact.
Risk Factors
- Phase 3 trial may fail to meet endpoints, leading to stock decline.
- Micro-cap biotech with limited cash runway and high dilution risk.
- No new efficacy or safety data provided in this announcement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328357 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers